Drug Search Results
More Filters [+]

GSK-3745417

Alternative Names: GSK-3745417, GSK3745417, GSK 3745417
Latest Update: 2024-09-27
Latest Update Note: Clinical Trial Update

Product Description

An agonist of the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential immunoactivating and antineoplastic activities. Upon intravenous administration, STING agonist GSK3745417 targets and binds to STING and activates the STING pathway in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs), enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs), and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-gsk3745417)

Mechanisms of Action: STING Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GSK-3745417

Countries in Clinic: Australia, Canada, France, Japan, Korea, Netherlands, Spain, United States, Unknown Location

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

jRCT2031220077

P1

Active, not recruiting

Oncology Solid Tumor Unspecified

2024-07-17

NCT03843359

P1

Active, not recruiting

Oncology Solid Tumor Unspecified

2024-04-05

Recent News Events